Glycosylated haemoglobin

Glycosylated haemoglobin (HbA1c) is a form of hemoglobin that is chemically linked to a sugar. It is a valuable biomarker used in the monitoring and management of diabetes mellitus. The measurement of HbA1c levels provides a long-term indication of blood glucose control, reflecting average blood glucose levels over a period of approximately 2 to 3 months.

Overview

Glycosylated haemoglobin forms when glucose in the blood binds to hemoglobin, a protein in red blood cells that carries oxygen. The binding process is non-enzymatic and is known as glycation. The more glucose present in the blood, the more glycation occurs and the higher the HbA1c level. Since red blood cells have a lifespan of about 120 days, HbA1c levels represent the average glucose concentration over the life of the cells.

Clinical Significance

HbA1c testing is a cornerstone in the management of diabetes, providing a summary measure of glycemic control over time. It is used both for the diagnosis of diabetes and for monitoring the effectiveness of treatment strategies. Guidelines recommend that individuals with diabetes maintain HbA1c levels below a certain threshold to reduce the risk of complications such as neuropathy, retinopathy, nephropathy, and cardiovascular disease.

Measurement

The measurement of HbA1c is typically performed using high-performance liquid chromatography (HPLC), though other methods such as immunoassay and enzymatic assays are also used. The results are expressed as a percentage of total hemoglobin.

Interpretation

- Normal: Below 5.7% - Prediabetes: 5.7% to 6.4% - Diabetes: 6.5% or higher

It is important to note that certain conditions can affect the accuracy of HbA1c measurements, including hemoglobin variants, recent blood transfusions, and chronic kidney or liver disease.

Advantages and Limitations

The primary advantage of HbA1c testing is its ability to provide an integrated measure of blood glucose levels over an extended period, which is not influenced by short-term fluctuations due to stress, illness, or changes in diet. However, it does not provide information on daily glucose fluctuations and is not a substitute for regular blood glucose monitoring in individuals using insulin.

Conclusion

Glycosylated haemoglobin is a critical tool in the management of diabetes, offering a long-term view of an individual's blood glucose control. Its role in guiding treatment decisions underscores the importance of regular HbA1c testing in individuals with diabetes.

‎